The 5-HT2A receptor is a Gq-coupled GPCR expressed at high density on cortical layer V pyramidal neurons (especially prefrontal cortex) and is the obligate target of classical psychedelics — psilocin (active metabolite of psilocybin), LSD, DMT, mescaline, 5-MeO-DMT. Pharmacology distinguishes psychedelic from non-psychedelic 5-HT2A agonists: biased agonism for β-arrestin-2 + specific G-protein subtypes (Gq, but with downstream signaling that engages BDNF/mTOR — see bdnf trkb neurotrophic); recent evidence that psilocin + LSD bind TrkB directly (Moliner 2023) and that head-twitch response in rodents (a 5-HT2A psychedelic-specific behavior) tracks subjective "trip" intensity in humans. Functional mechanism: 5-HT2A → Gq → PLC → IP3 + DAG → Ca²⁺ + PKC → cortical pyramidal cell depolarization → glutamate release (especially on thalamic relay) → mGluR2/3 cross-talk modulates the experience (ketanserin blocks the experience; mGluR2 agonists dampen it). Persistent post-acute effects: ↑synaptogenesis in PFC (rapid, mTOR-dependent), ↑plasticity, ↓DMN connectivity (network "reset" hypothesis for depression/anxiety/addiction). 5-HT2A is also a major off-target for atypical antipsychotics (high 5-HT2A:D2 ratio defines "atypicality" per Meltzer hypothesis — clozapine, olanzapine, risperidone, quetiapine block 5-HT2A → ↓EPS, ↑metabolic effects). Pure 5-HT2A inverse agonists: pimavanserin (Parkinson disease psychosis — no D2 blockade); historic ritanserin (depression trials, failed). Therapeutics — psychedelic: psilocybin (COMP360 in TRD phase 3); MDMA (PTSD — Lykos); LSD trials. Anti-psychotic: pimavanserin selective; nuplazid. Cross-links: serotonin receptor pharmacology (parent), bdnf trkb neurotrophic (downstream psychoplastogen mechanism), mglur metabotropic glutamate (mGluR2/3 modulation of psychedelic).
Organ Systems
nervous
Pathway Steps
psilocybin (PO) → psilocin (active) — via alkaline phosphatase + non-specific esterase dephosphorylation; not CYP. Psilocybin is a prodrug: intestinal and blood phosphatases rapidly dephosphorylate it to psilocin, the actual psychoactive molecule. This conversion is why oral psilocybin has a delayed, smoother onset than psilocin itself, and underlies its dosing in clinical trials for depression.
psilocin / LSD / DMT → 5-HT2A receptor activation (Gq biased) — via cortical layer V pyramidal neuron; β-arrestin-2 + Gq engagement. The classic psychedelics — psilocin, LSD, DMT — act as agonists at the 5-HT2A serotonin receptor, the necessary target for their subjective effects (blocked by the antagonist ketanserin). They engage Gq signaling with a distinctive profile that may distinguish hallucinogenic from non-hallucinogenic 5-HT2A agonists.
5-HT2A → Gq → PLC → IP3 + DAG → Ca²⁺ + PKC — via cortical pyramidal depolarization. 5-HT2A couples to Gq, activating phospholipase C to generate IP3 and DAG — raising intracellular Ca²⁺ and activating PKC. On cortical pyramidal neurons this is excitatory, and the resulting signaling is the proximal trigger for the downstream glutamatergic and plasticity effects of psychedelics.
cortical pyramidal glutamate release → mGluR2/3 + AMPA modulation — via thalamic relay disruption; mGluR2 agonists block subjective effect. 5-HT2A activation on layer-5 cortical pyramidal neurons increases glutamate release, engaging AMPA receptors and presynaptic mGluR2/3. This cortical glutamate surge is thought to underlie the perceptual effects, and the mGluR2/3 interaction is why mGluR2 agonists can dampen psychedelic effects.
psilocin / LSD → TrkB direct binding (Moliner 2023) — via distinct from 5-HT2A — psychoplastogen mechanism; supports BDNF cross-link. Beyond 5-HT2A, psychedelics were shown to bind the BDNF receptor TrkB directly (Moliner et al. 2023), promoting neurotrophic signaling and plasticity. This receptor action — distinct from the 5-HT2A-mediated subjective trip — may help explain the lasting antidepressant, pro-plasticity effects.
sustained 5-HT2A → mTOR → PFC synaptogenesis (24–48 h) — via rapid, mTOR-dependent; persists weeks (ketamine-like mechanism). Sustained 5-HT2A signaling activates mTOR-dependent protein synthesis, driving structural synaptogenesis (new dendritic spines) in the prefrontal cortex over ~24-48 h. This delayed plasticity, rather than the acute experience, is increasingly seen as the substrate of psychedelics’ durable therapeutic effects.